Toleranzia
0.598 SEK +0.34%Be the first to follow this company
Toleranzia is a research company focused on the development of drug candidates for the treatment of autoimmune diseases. The company has developed a platform technology focused on the muscular disease myasthenia gravis. In addition, the technology has been used in other areas such as diabetes and multiple sclerosis. Research collaboration is done together with external partners within the field. The head office is based in Gothenburg.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
TOL
Daily low / high price
0.576 / 0.6
SEK
Market cap
117.85M SEK
Turnover
56.49K SEK
Volume
95K
Financial calendar
Interim report
2024-08-23
Interim report
2024-10-24
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Flerie Invest AB | 57.1 % | 57.1 % |
Avanza Pension | 3.4 % | 3.4 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Toleranzia AB appoints Ann-Sofie Taube as CFO of the company on an interim basis
Kommuniké från årsstämman 2024 i Toleranzia AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools